secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001104659-25-018212
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance Q4 2024 product revenue $73.7M; FY24 total $164.1M, achieving upper end of guidance
--------------------------------------------------------------------------------

- Full year 2024 product revenue of $164.1M, within $160-165M guidance; Amtagvi $103.6M, Proleukin $60.5M.
- Net loss FY24 $372.2M ($1.28/share) vs $444.0M ($1.89/share) in FY23.
- Reaffirms FY25 product revenue guidance of $450-475M; FY25 cash burn expected under $300M.
- Cash position ~$422M as of Feb 26, 2025, expected to fund operations into H2 2026.
- Dan Kirby named Chief Commercial Officer in Feb 2025; Raj Puri promoted to Chief Regulatory Officer Nov 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465925018212/0001104659-25-018212-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465925018212/tm257755d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-018212

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer